A Phase 1 interventional study of NGM120 and Placebo in Cachexia, sponsored by NGM Biopharmaceuticals, Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by NGM Biopharmaceuticals, Inc · Phase 1, Interventional, and Treatment
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
Exclusion Criteria:
Single Dose
Biological: NGM120
Single Dose
Other: Placebo
Multiple Dose
Biological: NGM120
Multiple Dose
Other: Placebo
Subcutaneous Injection
Subcutaneous Injection
Part A Arm-Single Dose: Treatment Emergent Adverse events
Percentage of total subjects with Treatment Emergent Adverse event
Time frame: 28 days
Part B Arm-Multiple Dose: Treatment Emergent Adverse events
Percentage of total subjects with Treatment Emergent Adverse event
Time frame: 84 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NGM Biopharmaceuticals, Inc